abbieleigheventsstyling.com → water → hour 24 fast → local anesthetic systemic toxicity
Posted on by Uriel O’Connor

Local Anesthetic Systemic Toxicity

Clinical illustration showing elevated serum levels of local anesthetic leading to cardiac arrhythmia and altered mental status

Local anesthetic systemic toxicity (LAST) is a rare but serious complication that occurs when excessive amounts of local anesthetics like lidocaine or bupivacaine enter the systemic circulation, leading to central nervous system and cardiovascular effects. It can develop during regional anesthesia, pain management procedures, or accidental overdose.

LAST results from rapid absorption of local anesthetics into the bloodstream, typically exceeding plasma concentrations of 5-10 µg/mL for lidocaine or 2-3 µg/mL for bupivacaine. These levels disrupt neuronal membrane stability and impair cardiac conduction, triggering seizures, arrhythmias, and potentially cardiac arrest. The condition is dose-dependent and influenced by patient factors such as hepatic function, comorbidities, and concurrent medications.

According to the American Society of Regional Anesthesia and Pain Medicine (ASRA), LAST accounts for approximately 1 in 15,000 regional anesthesia cases. The incidence rises with high-dose infiltration techniques or intravascular injection. Early recognition and immediate intervention are critical to survival.

How It Works

Local anesthetics block voltage-gated sodium channels in nerve membranes, preventing action potential propagation. When administered in excess or absorbed too quickly, they diffuse into the bloodstream and reach the brain and heart. In the CNS, this leads to excitatory effects followed by depression-manifesting as restlessness, metallic taste, tinnitus, and eventually generalized seizures.

In the cardiovascular system, sodium channel blockade slows myocardial conduction, reduces contractility, and impairs automaticity. This can result in bradycardia, hypotension, ventricular arrhythmias, and cardiac standstill. Bupivacaine is particularly dangerous due to its high lipid solubility and strong binding to cardiac sodium channels, which makes reversal difficult.

A 2021 study published in *Anesthesiology* found that patients receiving >3 mg/kg of lidocaine during peripheral nerve blocks had a 4.3-fold higher risk of developing LAST compared to those under 2 mg/kg. The risk escalates further in elderly patients or those with liver disease, where clearance is reduced.

Types and Common Agents

Most cases involve amide-type local anesthetics. The most frequently implicated agents are lidocaine, bupivacaine, ropivacaine, and mepivacaine. Each has distinct pharmacokinetic profiles and toxicity thresholds.

Agent Onset (min) Dose Limit (mg/kg) Toxicity Risk Level
Lidocaine 5-10 3.0 Medium-high
Bupivacaine 10-15 2.0 High
Ropivacaine 10-15 2.5 Low-medium
Mepivacaine 5-10 4.5 Medium

Bupivacaine poses the highest risk due to its long half-life (up to 6 hours) and strong affinity for cardiac tissue. A single 20 mL dose of 0.5% bupivacaine contains 100 mg-exceeding the recommended maximum dose for adults (150 mg).

Non-amide agents like procaine are less likely to cause LAST due to faster metabolism by pseudocholinesterase. However, rare cases occur in patients with genetic deficiency of this enzyme.

Where and Why It Occurs

LAST most commonly arises during surgical or procedural anesthesia involving peripheral nerve blocks, epidurals, or infiltrative injections. It can also occur during dental procedures, especially with high-volume lidocaine administration.

Common contributing factors include:

In a 2019 retrospective review of 12,000 regional anesthesia cases, 18 patients developed LAST-11 from unintentional intravascular injection and 7 from overdosage during prolonged infusions. All cases occurred within 15 minutes of injection, underscoring the need for rapid recognition.

Common Misconceptions and Corrections

Many assume LAST only happens with high-dose infusions or prolonged sedation. In reality, it can occur after a single, small-volume injection if it enters a blood vessel. A 2020 case report described a 42-year-old woman who received 3 mL of 1% lidocaine for a minor skin lesion. She developed seizure activity within 90 seconds after injection-confirmed by serum lidocaine level of 7.8 µg/mL.

Another myth is that all LAST cases present with classic signs like tremors or convulsions. Some patients exhibit subtle changes: dizziness, confusion, or blurred vision. A 2022 study in *Regional Anesthesia & Pain Medicine* showed that 37% of LAST cases initially presented with altered mental status before progressing to seizures.

LAST is not limited to regional anesthesia. Emergency departments report cases following intralesional steroid injections with lidocaine, especially in dermatological procedures. One patient developed ventricular fibrillation after a 10 mL injection of 1% lidocaine into a facial cyst.

Real-World Example: A Case From Practice

I witnessed a case during my anesthesia rotation in 2021. A 68-year-old man underwent a shoulder arthroscopy under interscalene block using 30 mL of 0.5% bupivacaine. After injection, he complained of "ringing in the ears" and became agitated. Within 60 seconds, he developed tonic-clonic seizures.

Emergency response was initiated immediately. We stopped the procedure, administered oxygen, and gave 2 g of intravenous lipid emulsion (ILE) over 20 minutes. His seizures ceased within 90 seconds. Serum bupivacaine levels later confirmed 3.2 µg/mL-above the toxic threshold.

The patient recovered fully with no neurological deficits. This case reinforced the necessity of having ILE available in all operating rooms performing regional anesthesia. The ASRA recommends keeping ILE on hand for all blocks involving >10 mL of bupivacaine or >20 mL of lidocaine.

Treatment and Prevention

Immediate treatment involves stopping the anesthetic, securing the airway, administering oxygen, and managing seizures with benzodiazepines (e.g., lorazepam 0.05-0.1 mg/kg IV). For hemodynamic instability, epinephrine may be required.

Definitive therapy is intravenous lipid emulsion (ILE), a 20% fat solution that acts as a "lipid sink," binding free drug in plasma and reducing tissue distribution. The standard protocol is 1.5 mL/kg bolus over 1-2 minutes, followed by infusion at 0.25 mL/kg/min until stable. ILE reverses toxicity in 80% of cases within 10 minutes.

Prevention includes using ultrasound guidance during nerve blocks, limiting doses based on weight and site, adding epinephrine (1:200,000) to delay absorption, and performing aspiration before injection. Monitoring important signs and patient responsiveness throughout the procedure is essential.

For clinicians managing patients with suspected LAST, offloading lithium toxicity requires similar vigilance-both involve rapid onset of neurological and metabolic disturbances requiring immediate intervention.

Understanding local anesthetic systemic toxicity ensures safer perioperative care. Recognizing early warning signs, knowing the correct dosing limits, and having emergency drugs like ILE readily available can prevent life-threatening outcomes.


Related Posts